Table 3.
Changes in anthropometric assessment over 8-week study period
| Aripiprazole (N=16) | Placebo (N=14) | p | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||
| Baseline | Week 8 change | Baseline | Week 8 change | ||||||
|
|
|||||||||
| Variable | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Body weight (kg) | 90.9 | 19.7 | −1.5 | 2.3 | 103.9 | 23.8 | 0.3 | 2.3 | 0.109 |
| BMI (kg/m2) | 30.66 | 5.99 | −0.52 | 0.79 | 35.41 | 7.29 | 0.03 | 0.85 | 0.229 |
| Waist circumference (umbilicus, cm) | 108.8 | 15.2 | −0.4 | 2.3 | 120 | 16.0 | −0.8 | 4.2 | 0.754 |
| DXA BMC (g) | |||||||||
| Trunk | 623 | 135 | 8 | 17 | 697 | 199 | −16 | 48 | 0.317 |
| Total body | 2,473 | 482 | 28 | 46 | 2,566 | 493 | −4 | 61 | 0.145 |
| DXA fat mass (g) | |||||||||
| Trunk | 14,740 | 6,162 | −326 | 699 | 19,828 | 6,698 | 19 | 822 | 0.514 |
| Total body | 29,054 | 10,489 | −633 | 1,055 | 37,691 | 12,211 | 2 | 1,137 | 0.321 |
| DXA fat percentage (%) | |||||||||
| Trunk | 31.5 | 8.0 | −0.1 | 1.4 | 38.4 | 7.9 | −0.2 | 0.8 | 0.521 |
| Total body | 30.7 | 6.7 | −0.2 | 0.8 | 36.8 | 7.8 | −0.2 | 0.6 | 0.617 |
| DXA lean mass (g) | |||||||||
| Trunk | 29,631 | 4,463 | −641 | 903 | 30,166 | 5,050 | 253 | 689 | 0.010 |
| Total body | 61,314 | 12,637 | −1,125 | 1,620 | 60,602 | 10,574 | 607 | 1,578 | 0.011 |
| DXA total mass (g) | |||||||||
| Trunk | 44,995 | 9,381 | −960 | 1,032 | 50,691 | 9,962 | 256 | 1,306 | 0.037 |
| Total body | 92,841 | 19,948 | −1,730 | 2,132 | 100,859 | 18,903 | 602 | 2,273 | 0.016 |
Week 8 change equals week 8 value minus baseline value.
P vales were based on ANCOVA comparing between group differences in week 8 changes controlling for baseline values.
BMI, body mass index; DXA, dual-energy X-ray absorptiometry; BMC, bone mineral content.